Molecular targets for liver cancer therapy: From screening of target genes to clinical trials

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Hepatology Research

• Publication date

  2010-01-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1111/j.1872-034X.2009.00583.xPMID 19788683
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma.

  2009cited by this paper
• The knockdown of endogenous replication factor C4 decreases the growth and enhances the chemosensitivity of hepatocellular carcinoma cells

  2009cited by this paper
• Allelic imbalances and homozygous deletion on 8p23.2 for stepwise progression of hepatocarcinogenesis

  2009cited by this paper
• EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features.

  2009cited by this paper
• Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study.

  2009cited by this paper
• Anti-glypican 3 antibodies cause ADCC against human hepatocellular carcinoma cells.

  2009cited by this paper
• TOP2A overexpression in hepatocellular carcinoma correlates with early age onset, shorter patients survival and chemoresistance

  2009cited by this paper
• CREB3L4, INTS3, and SNAPAP are targets for the 1q21 amplicon frequently detected in hepatocellular carcinoma.

  2008cited by this paper
• Granulin‐epithelin precursor as a therapeutic target for hepatocellular carcinoma

  2008cited by this paper
• Screening of liver-targeted drugs

  2008cited by this paper
• Gene expression in fixed tissues and outcome in hepatocellular carcinoma.

  2008cited by this paper
• Reactivation of the insulin-like growth factor-II signaling pathway in human hepatocellular carcinoma.

  2008cited by this paper
• Phase II Study of Imatinib in Unresectable Hepatocellular Carcinoma

  2008cited by this paper
• Aberrant methylation of multiple tumor suppressor genes in aging liver, chronic hepatitis, and hepatocellular carcinoma

  2008cited by this paper
• Aurora kinase B is a predictive factor for the aggressive recurrence of hepatocellular carcinoma after curative hepatectomy

  2008cited by this paper
• Development of sorafenib and other molecularly targeted agents in hepatocellular carcinoma

  2008cited by this paper
• Identification of SOX4 target genes using phylogenetic footprinting-based prediction from expression microarrays suggests that overexpression of SOX4 potentiates metastasis in hepatocellular carcinoma

  2008cited by this paper
• Sorafenib in advanced hepatocellular carcinoma.

  2008cited by this paper
• Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma

  2008cited by this paper
• ABT-869, a multi-targeted tyrosine kinase inhibitor, in combination with rapamycin is effective for subcutaneous hepatocellular carcinoma xenograft.

  2008cited by this paper
• High-resolution mapping of DNA hypermethylation and hypomethylation in lung cancer

  2008cited by this paper
• Autocrine insulin‐like growth factor‐II stimulation of tumor cell migration is a progression step in human hepatocarcinogenesis

  2008cited by this paper
• Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma.

  2008cited by this paper
• Anti-glypican 3 antibody as a potential antitumor agent for human liver cancer.

  2008cited by this paper
• Human homolog of NOTUM, overexpressed in hepatocellular carcinoma, is regulated transcriptionally by β‐catenin/TCF

  2008cited by this paper
• Sorafenib in advanced hepatocellular carcinoma.

  2008cited by this paper
• Focal gains of VEGFA and molecular classification of hepatocellular carcinoma.

  2008cited by this paper
• Effect of Rapamycin Alone and in Combination with Sorafenib in an Orthotopic Model of Human Hepatocellular Carcinoma

  2008cited by this paper
• Epithelial-to-mesenchymal transition and integrin-linked kinase mediate sensitivity to epidermal growth factor receptor inhibition in human hepatoma cells.

  2008cited by this paper
• MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations

  2008cited by this paper
• Identification of genes associated with multiple nodules in hepatocellular carcinoma using cDNA microarray: multicentric occurrence or intrahepatic metastasis?

  2008cited by this paper
• Identification of Cystatin B as a Potential Serum Marker in Hepatocellular Carcinoma

  2008cited by this paper
• Pivotal role of mTOR signaling in hepatocellular carcinoma.

  2008cited by this paper
• Mechanistic and prognostic significance of aberrant methylation in the molecular pathogenesis of human hepatocellular carcinoma.

  2007cited by this paper
• Microarray-based analysis for hepatocellular carcinoma: from gene expression profiling to new challenges.

  2007cited by this paper
• Platelet-derived growth factor receptor-α: a novel therapeutic target in human hepatocellular cancer

  2007cited by this paper
• Role of hepatocyte growth factor/c-Met signaling in regulating urokinase plasminogen activator on invasiveness in human hepatocellular carcinoma: a potential therapeutic target

  2007cited by this paper
• Identification of PEG10 as a progression related biomarker for hepatocellular carcinoma.

  2007cited by this paper
• MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer.

  2007cited by this paper
• Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma

  2007cited by this paper
• Identification of PFTAIRE protein kinase 1, a novel cell division cycle‐2 related gene, in the motile phenotype of hepatocellular carcinoma cells

  2007cited by this paper
• Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma

  2007cited by this paper
• Tissue factor pathway inhibitor‐2 as a frequently silenced tumor suppressor gene in hepatocellular carcinoma

  2007cited by this paper
• In vitro c-met inhibition by antisense RNA and plasmid-based RNAi down-modulates migration and invasion of hepatocellular carcinoma cells.

  2007cited by this paper
• FLJ10540-elicited cell transformation is through the activation of PI3-kinase/AKT pathway

  2007cited by this paper
• Genome‐wide molecular profiles of HCV‐induced dysplasia and hepatocellular carcinoma

  2007cited by this paper
• Integration of genomic analysis and in vivo transfection to identify sprouty 2 as a candidate tumor suppressor in liver cancer

  2007cited by this paper
• Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma.

  2007cited by this paper
• Discovery of epigenetically silenced genes by methylated DNA immunoprecipitation in colon cancer cells.

  2007cited by this paper
• Elevated expression and potential roles of human Sp5, a member of Sp transcription factor family, in human cancers.

  2006cited by this paper
• PTEN/Akt signaling through epidermal growth factor receptor is prerequisite for angiogenesis by hepatocellular carcinoma cells that is susceptible to inhibition by gefitinib.

  2006cited by this paper
• Molecular karyotyping of human hepatocellular carcinoma using single-nucleotide polymorphism arrays

  2006cited by this paper
• Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma.

  2006cited by this paper
• Oncomirs — microRNAs with a role in cancer

  2006cited by this paper
• Identification of Carboxypeptidase of Glutamate Like-B as a Candidate Suppressor in Cell Growth and Metastasis in Human Hepatocellular Carcinoma

  2006cited by this paper
• Identification of HLA-A2- or HLA-A24-Restricted CTL Epitopes Possibly Useful for Glypican-3-Specific Immunotherapy of Hepatocellular Carcinoma

  2006cited by this paper
• Activation of the hedgehog pathway in human hepatocellular carcinomas.

  2006cited by this paper
• Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.

  2006cited by this paper
• Novel identification of zyxin upregulations in the motile phenotype of hepatocellular carcinoma

  2006cited by this paper
• Identification of ROBO1 as a Novel Hepatocellular Carcinoma Antigen and a Potential Therapeutic and Diagnostic Target

  2006cited by this paper
• Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues

  2006cited by this paper
• TIPUH1 encodes a novel KRAB zinc-finger protein highly expressed in human hepatocellular carcinomas

  2006cited by this paper
• Hedgehog signaling in human hepatocellular carcinoma

  2006cited by this paper
• Identification and characterization of lin-28 homolog B (LIN28B) in human hepatocellular carcinoma.

  2006cited by this paper
• Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer.

  2005cited by this paper
• Current Status of Gendicine in China: Recombinant Human Ad-p53 Agent for Treatment of Cancers

  2005cited by this paper
• Exploiting the PI3K/AKT Pathway for Cancer Drug Discovery

  2005cited by this paper
• Allelic dosage analysis with genotyping microarrays.

  2005cited by this paper
• Epigenetic inactivation and aberrant transcription of CSMD1 in squamous cell carcinoma cell lines

  2005cited by this paper
• Regional over-representations on chromosomes 1q, 3q and 7q in the progression of hepatitis B virus-related hepatocellular carcinoma

  2005cited by this paper
• Array-based comparative genomic hybridization reveals recurrent chromosomal aberrations and Jab1 as a potential target for 8q gain in hepatocellular carcinoma.

  2005cited by this paper
• The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma

  2005cited by this paper
• Targeting the platelet-derived growth factor receptor α with a neutralizing human monoclonal antibody inhibits the growth of tumor xenografts: Implications as a potential therapeutic target

  2005cited by this paper
• Pharmacokinetic and Clinical Phase II Trial of Imatinib in Patients with Impaired Liver Function and Advanced Hepatocellular Carcinoma

  2005cited by this paper
• Ephrin-A1 expression contributes to the malignant characteristics of α-fetoprotein producing hepatocellular carcinoma

  2005cited by this paper
• WDRPUH, a novel WD-repeat-containing protein, is highly expressed in human hepatocellular carcinoma and involved in cell proliferation.

  2005cited by this paper
• Gefitinib, an EGFR inhibitor, prevents hepatocellular carcinoma development in the rat liver with cirrhosis

  2005cited by this paper
• Granulin–Epithelin Precursor Overexpression Promotes Growth and Invasion of Hepatocellular Carcinoma

  2004cited by this paper
• Identification of Soluble NH2-Terminal Fragment of Glypican-3 as a Serological Marker for Early-Stage Hepatocellular Carcinoma

  2004cited by this paper
• Anticancer drugs: To the rescue?

  2004cited by this paper
• Distinct Chromosomal Bias of Gene Expression Signatures in the Progression of Hepatocellular Carcinoma

  2004cited by this paper
• Targeting the epidermal growth factor receptor by gefitinib for treatment of hepatocellular carcinoma.

  2004cited by this paper
• SU5416 is a potent inhibitor of hepatocyte growth factor receptor (c-Met) and blocks HGF-induced invasiveness of human HepG2 hepatoma cells.

  2004cited by this paper
• Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

  2004cited by this paper
• MicroRNAs: small RNAs with a big role in gene regulation

  2004cited by this paper
• Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

  2004cited by this paper
• Isolation of development and differentiation enhancing factor-like 1 (DDEFL1) as a drug target for hepatocellular carcinomas.

  2004cited by this paper
• Aberrant promoter methylation profiles of tumor suppressor genes in hepatocellular carcinoma.

  2003cited by this paper
• Antisense overexpression of BMAL2 enhances cell proliferation

  2003cited by this paper
• Glypican‐3, overexpressed in hepatocellular carcinoma, modulates FGF2 and BMP‐7 signaling

  2003cited by this paper
• The presence of multiple regions of homozygous deletion at the CSMD1 locus in oral squamous cell carcinoma question the role of CSMD1 in head and neck carcinogenesis

  2003cited by this paper
• Gene silencing in cancer in association with promoter hypermethylation.

  2003cited by this paper
• Glypican‐3 is overexpressed in human hepatocellular carcinoma

  2003cited by this paper
• Involvement of PEG10 in human hepatocellular carcinogenesis through interaction with SIAH1.

  2003cited by this paper
• Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker.

  2003cited by this paper
• Expression imbalance map: a new visualization method for detection of mRNA expression imbalance regions.

  2003cited by this paper
• Identification of Genes Associated with Dedifferentiation of Hepatocellular Carcinoma with Expression Profiling Analysis

  2002cited by this paper
• Isolation and characterization of a novel human gene, VANGL1, as a therapeutic target for hepatocellular carcinoma.

  2002cited by this paper
• Gene expression patterns in human liver cancers.

  2002cited by this paper
• Comparison of gene expression profiles between hepatitis B virus- and hepatitis C virus-infected hepatocellular carcinoma by oligonucleotide microarray data on the basis of a supervised learning method.

  2002cited by this paper

• A FOXM1-Targeted Peptide Overcomes 5-Fluorouracil Resistance via Modulating ABC Transporters in Liver Cancer HepG2 Cells

  2021cites this paper
• High expression of chaperonin-containing TCP1 subunit 3 may induce dismal prognosis in multiple myeloma

  2020cites this paper
• The antioxidant and anticancer potential of Ricinus communis L. essential oil nanoemulsions

  2020cites this paper
• Pine needle oil induces G2/M arrest of HepG2 cells by activating the ATM pathway

  2017cites this paper
• A multi‑targeted tyrosine kinase inhibitor lenvatinib for the treatment of mice with advanced glioblastoma.

  2017cites this paper
• Molecular alterations in hepatocellular carcinoma associated with hepatitis B and hepatitis C infections

  2016cites this paper
• Activation of RAS/ERK alone is insufficient to inhibit RXRα function and deplete retinoic acid in hepatocytes.

  2014cites this paper
• Efecto de la melatonina sobre la proliferación, apoptosis y angiogénesis en un modelo in vitro de hepatocarcinoma

  2013cites this paper
• Carcinoma hepatocelular: epidemiologia, biologia, diagnóstico e terapias

  2013cites this paper
• Transcript Profiling Identifies Iqgap2−/− Mouse as a Model for Advanced Human Hepatocellular Carcinoma

  2013cites this paper
• Enhanced binding to and killing of hepatocellular carcinoma cells in vitro by melittin when linked with a novel targeting peptide screened from phage display

  2013cites this paper
• Hepatocellular carcinoma: epidemiology, biology, diagnosis, and therapies.

  2013cites this paper
• Molecular Signatures Associated with HCV-Induced Hepatocellular Carcinoma and Liver Metastasis

  2013cites this paper
• ASSOCIAÇÃO MÉDICA BRASILEIRA

  2013cites this paper
• Inhibition of VEGF expression through blockade of Hif1α and STAT3 signalling mediates the anti-angiogenic effect of melatonin in HepG2 liver cancer cells

  2013cites this paper
• Hepatocellular carcinoma: epidemiology, biology, diagnosis, and therapies

  2013cites this paper
• Hepatocellular carcinoma : epidemiology , biology , diagnosis , and therapies q

  2013cites this paper
• Tg737 inhibition results in malignant transformation in fetal liver stem/progenitor cells by promoting cell‐cycle progression and differentiation arrest

  2012cites this paper
• Percutaneous methods for ablating liver tumors

  2012cites this paper
• Screening and Identification of Polypeptides Specifically Binding to Hepatoma Carcinoma Cells

  2012cites this paper
• Activation of PI3K/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells

  2011cites this paper
• Effects of raspberry phytochemical extract on cell proliferation, apoptosis, and serum proteomics in a rat model.

  2011cites this paper
• Activation of Phosphatidylinositol 3-Kinase/Akt Signaling Pathway Mediates Acquired Resistance to Sorafenib in Hepatocellular Carcinoma Cells

  2011cites this paper
• Molecular Genetic Pathology of Solid Tumors

  2011cites this paper
• Review Article Molecular genetics of hepatocellular neoplasia

  2010cites this paper
• Molecular genetics of hepatocellular neoplasia.

  2010cites this paper
• Genetic and functional characterization of putative Ras/Raf interaction inhibitors in C. elegans and mammalian cells

  2010cites this paper